文献速递垂体与肾上腺疾病

卡博替尼治疗晚期肾上腺皮质癌的客观缓解与疾病长期控制

Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项回顾性队列研究在德国和美国三个转诊中心纳入16例进展期肾上腺皮质癌患者,评估卡博替尼单药治疗的疗效与安全性。最佳缓解为部分缓解3例、疾病稳定5例、疾病进展8例;中位无进展生存期16周,中位总生存期58周。作者认为卡博替尼单药在既往治疗失败后的晚期肾上腺皮质癌中似乎安全有效,值得前瞻性研究。

要点

  • 16例进展期肾上腺皮质癌患者接受卡博替尼单药治疗,其中15例既往使用过米托坦。
  • 最佳缓解:部分缓解3例,疾病稳定5例,疾病进展8例。
  • 中位无进展生存期16周,中位总生存期58周;1/2级和3级不良事件分别见于13例和3例。

核心结论

  • 卡博替尼单药在既往治疗失败后的晚期肾上腺皮质癌中似乎安全有效,因此有必要对卡博替尼在肾上腺皮质癌患者中进行前瞻性研究。

研究设计与样本

  • 回顾性队列研究,在德国和美国的三个肾上腺皮质癌转诊中心开展,纳入16例进展期肾上腺皮质癌患者(女性13例)。
  • 15/16例既往接受过米托坦,既往接受其他全身治疗的中位数为3种(范围0-8种);开始卡博替尼前所有患者均已停用米托坦。
  • 开始卡博替尼前,7/16例患者米托坦血浆浓度低于2 mg/L,另有6例已停用米托坦超过12个月。
  • 在5例有可用血浆样本的患者中,4例的卡博替尼浓度处于预期稳态范围。

主要发现

  • 最佳缓解为部分缓解3例、疾病稳定5例、疾病进展8例。
  • 中位无进展生存期为16周,中位总生存期为58周。
  • 1/2级和3级不良事件分别见于13例和3例患者,与卡博替尼已知的安全性特征一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. Previous clinical trials with oral multikinase inhibitors were negative, which has been attributed in part to inadvertent drug interaction with mitotane. Cabozantinib (CABO) is an inhibitor of c-MET, vascular endothelial growth factor receptor 2, AXL, and RET and approved for advanced kidney cancer, liver carcinoma after previous sorafenib, and medullary thyroid carcinoma. OBJECTIVE: To investigate the clinical efficacy and safety of CABO monotherapy in ACC patients. DESIGN: Retrospective cohort study. SETTING: Three referral centers for ACC (Germany, United States). RESULTS: Sixteen patients (13 female) with progressive ACC received CABO after previous mitotane in 15/16 and 3 (median, range 0-8) further systemic treatments. Prior CABO therapy, mitotane was discontinued in all patients. Mitotane plasma concentration was <2 mg/L in 7/16 patients and discontinued >12 months in 6 additional patients before CABO use. In 4/5 cases with available plasma samples, CABO concentration was in the expected steady-state range. Adverse events of grade 1/2 and 3 were observed in 13 and 3 patients, respectively, and consistent with the known safety profile of CABO. Best response was partial response in 3, stable disease in 5, and progressive disease in 8 patients. Median progression-free and overall survival was 16 and 58 weeks, respectively. CONCLUSION: CABO monotherapy appears to be safe and effective as a monotherapy in advanced ACC after failing prior treatments. Therefore, prospective investigation of CABO in ACC patients is warranted.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kroiss M, Megerle F, Kurlbaum M, et al. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J Clin Endocrinol Metab. 2020. PMID: 31900481. doi:10.1210/clinem/dgz318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。